Application of the adenosine triphosphate sensitivity assay in infantile vascular anomalies

BMC Pediatrics

Table 1 Testing result of 5 cases infantile hemangiomas specimens, growth inhibition rates (%)

Testing drug	400%	200%	100%	50%	25%	12.5%	TGI
Patient No.1
Propranolol	18.04	8.83	9.95	5.34	3.81	1.16	47.13
Rapamycin	19.02	44.87	19.10	25.21	16.75	24.26	149.21
Sildenafil	2.13	−9.31	−14.08	−19.25	−38.13	−46.28	− 124.92
Itraconazole	49.77	58.43	18.98	−22.85	8.56	17.01	129.9
Patient No.2
Propranolol	27.99	18.03	22.05	18.63	18.59	20.94	126.23
Rapamycin	27.06	14.24	5.91	5.28	87.19	10.31	149.99
Sildenafil	15.02	−29.00	−13.13	−23.39	−12.60	−8.77	−71.87
Itraconazole	12.06	45.79	53.04	25.30	−8.01	53.94	182.12
Patient No.3
Propranolol	23.06	23.27	27.94	0.86	11.55	32.94	119.62
Rapamycin	42.99	44.02	35.61	38.37	39.46	32.60	233.05
Sildenafil	−11.26	−1.60	−13.39	− 10.91	−1.42	− 15.48	− 54.06
Itraconazole	32.02	23.12	13.06	2.13	−8.28	−10.31	51.74
Patient No.4
Propranolol	32.76	13.54	40.21	36.66	42.37	31.43	196.97
Rapamycin	13.03	56.73	8.15	50.81	45.72	11.57	186.01
Sildenafil	−6.90	16.45	18.61	26.69	15.26	−7.27	62.84
Patient No.5
Propranolol	4.29	6.24	0.50	11.70	8.31	13.53	44.57
Rapamycin	42.84	56.01	52.12	48.74	47.45	37.93	285.09
Sildenafil	12.36	8.49	−7.87	5.00	−7.87	−7.90	2.21

TGI total growth inhibition rate, summation of the percentage of growth inhibition at every testing concentration

ISSN: 1471-2431